141 related articles for article (PubMed ID: 24596468)
1. Management of sacroiliac joint disruption and degenerative sacroiliitis with nonoperative care is medical resource-intensive and costly in a United States commercial payer population.
Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J
Clinicoecon Outcomes Res; 2014; 6():63-74. PubMed ID: 24596468
[TBL] [Abstract][Full Text] [Related]
2. Nonoperative care to manage sacroiliac joint disruption and degenerative sacroiliitis: high costs and medical resource utilization in the United States Medicare population.
Ackerman SJ; Polly DW; Knight T; Holt T; Cummings J
J Neurosurg Spine; 2014 Apr; 20(4):354-63. PubMed ID: 24527824
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the costs of nonoperative care to minimally invasive surgery for sacroiliac joint disruption and degenerative sacroiliitis in a United States commercial payer population: potential economic implications of a new minimally invasive technology.
Ackerman SJ; Polly DW; Knight T; Schneider K; Holt T; Cummings J
Clinicoecon Outcomes Res; 2014; 6():283-96. PubMed ID: 24904218
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the costs of nonoperative care to minimally invasive surgery for sacroiliac joint disruption and degenerative sacroiliitis in a United States Medicare population: potential economic implications of a new minimally-invasive technology.
Ackerman SJ; Polly DW; Knight T; Schneider K; Holt T; Cummings J
Clinicoecon Outcomes Res; 2013; 5():575-87. PubMed ID: 24348055
[TBL] [Abstract][Full Text] [Related]
5. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
6. Impact of dyspnea on medical utilization and affiliated costs in patients with acute coronary syndrome.
Bonafede M; Jing Y; Gdovin Bergeson J; Liffmann D; Makenbaeva D; Graham J; Deitelzweig SB
Hosp Pract (1995); 2011 Aug; 39(3):16-22. PubMed ID: 21881388
[TBL] [Abstract][Full Text] [Related]
7. Analysis of postmarket complaints database for the iFuse SI Joint Fusion System®: a minimally invasive treatment for degenerative sacroiliitis and sacroiliac joint disruption.
Miller LE; Reckling WC; Block JE
Med Devices (Auckl); 2013; 6():77-84. PubMed ID: 23761982
[TBL] [Abstract][Full Text] [Related]
8. Healthcare resource use and economic burden attributable to respiratory syncytial virus in the United States: a claims database analysis.
Amand C; Tong S; Kieffer A; Kyaw MH
BMC Health Serv Res; 2018 Apr; 18(1):294. PubMed ID: 29678177
[TBL] [Abstract][Full Text] [Related]
9. Burden of illness in patients with possible Lennox-Gastaut syndrome: A retrospective claims-based study.
Reaven NL; Funk SE; Montouris GD; Saurer TB; Story TJ
Epilepsy Behav; 2018 Nov; 88():66-73. PubMed ID: 30241056
[TBL] [Abstract][Full Text] [Related]
10. Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.
Pike C; Birnbaum HG; Schiller M; Sharma H; Burge R; Edgell ET
Pharmacoeconomics; 2010; 28(5):395-409. PubMed ID: 20402541
[TBL] [Abstract][Full Text] [Related]
11. Societal burden of cluster headache in the United States: a descriptive economic analysis.
Ford JH; Nero D; Kim G; Chu BC; Fowler R; Ahl J; Martinez JM
J Med Econ; 2018 Jan; 21(1):107-111. PubMed ID: 29125368
[TBL] [Abstract][Full Text] [Related]
12. The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.
Rice JB; White AG; Galebach P; Korenblat KM; Wagh A; Lovelace B; Wan GJ; Jamil K
Curr Med Res Opin; 2017 Aug; 33(8):1473-1480. PubMed ID: 28509578
[TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
Burudpakdee C; Lin HM; Wang W; Seetasith A; Zhu Y; Bonthapally V; Carson KR
J Med Econ; 2016 Oct; 19(10):965-72. PubMed ID: 27152635
[TBL] [Abstract][Full Text] [Related]
14. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans.
White RR; Lenhart G; Singhal PK; Insinga RP; Itzler RF; Pellissier JM; Segraves AW
Pharmacoeconomics; 2009; 27(9):781-92. PubMed ID: 19757871
[TBL] [Abstract][Full Text] [Related]
15. Long-term economic outcomes of ureteral injury in the United States.
McCarus SD; Shortridge EF; Kimura T; Feng Q; Han W; Jiang B
Curr Med Res Opin; 2024 Feb; 40(2):325-333. PubMed ID: 37961772
[TBL] [Abstract][Full Text] [Related]
16. Postoperative complications in patients undergoing minimally invasive sacroiliac fusion.
Schoell K; Buser Z; Jakoi A; Pham M; Patel NN; Hsieh PC; Liu JC; Wang JC
Spine J; 2016 Nov; 16(11):1324-1332. PubMed ID: 27349627
[TBL] [Abstract][Full Text] [Related]
17. Triangular Titanium Implants for Minimally Invasive Sacroiliac Joint Fusion: A Prospective Study.
Duhon BS; Cher DJ; Wine KD; Kovalsky DA; Lockstadt H;
Global Spine J; 2016 May; 6(3):257-69. PubMed ID: 27099817
[TBL] [Abstract][Full Text] [Related]
18. Direct and Indirect Healthcare Resource Utilization and Costs Among Migraine Patients in the United States.
Bonafede M; Sapra S; Shah N; Tepper S; Cappell K; Desai P
Headache; 2018 May; 58(5):700-714. PubMed ID: 29446063
[TBL] [Abstract][Full Text] [Related]
19. Economic burden of sarcoidosis in a commercially-insured population in the United States.
Rice JB; White A; Lopez A; Conway A; Wagh A; Nelson WW; Philbin M; Wan GJ
J Med Econ; 2017 Oct; 20(10):1048-1055. PubMed ID: 28678623
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes in patients diagnosed with systemic lupus erythematosus with versus without nephritis: results from an analysis of data from a US claims database.
Pelletier EM; Ogale S; Yu E; Brunetta P; Garg J
Clin Ther; 2009 Nov; 31(11):2653-64. PubMed ID: 20110008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
